Bluejay Diagnostics Announces Completion of SYMON‑II Patient Enrollment

What Happened

• Bluejay Diagnostics, Inc. (BJDX) announced the completion of patient enrollment in its ongoing SYMON‑II clinical trial. The company issued a press release dated July 21, 2026 and furnished that release under Regulation FD in an 8‑K filed on July 22, 2026.

Key Details

• Press release announcing enrollment completion: July 21, 2026.
• 8‑K filing date: July 22, 2026 (Item 7.01, Regulation FD Disclosure).
• Exhibit included with the filing: Press Release (Exhibit 99.1).
• Trial referenced: SYMON‑II (ongoing clinical trial).

Why It Matters

• Completion of patient enrollment is a clinical development milestone that typically allows a company to proceed to subsequent trial activities (e.g., follow‑up, data collection and analysis) and may reduce enrollment risk. For investors, this can signal progress toward future data readouts or regulatory milestones. The 8‑K simply furnished the press release under Regulation FD; it does not itself provide new data or results from the trial.